Author(s): Hajiaghayi M; Gholizadeh F; Rahbari N; Emamnia N; Shih SCC; Darlington PJ;

Introduction: Cancers often drive T cells toward an exhausted state characterized by impaired cytotoxicity and upregulation of inhibitory receptors (PD-1, TIM-3, CD38) and transcriptional regulators (TOX, NFATc1). Repeated stimulation in vitro is used to model this process, reflecting chronic antigen exposure in the tumor microenvironment. Stress-derived ...

Article GUID: 41906691

Author(s): Baez A; Hazel K; Guertin Z; Fong E; Manus MM; Kaloyannis A; Helfield B;

Adoptive cell transfer (ACT)-based immunotherapy has emerged as a transformative approach for treating cancer, offering durable responses through the ex vivo expansion and reinfusion of antigen-specific immune cells. Despite remarkable clinical successes, most notably with chimeric antigen receptor (CAR)-T cell therapy, ACT remains limited by severe toxic ...

Article GUID: 41748028

Author(s): Murphy J; Morais JA; Tsoukas MA; Cooke AB; Daskalopoulou SS; Santosa S;

Introduction: Adipose tissue inflammation, driven in part by immune cells, may contribute to the elevated type 2 diabetes risk in adults with childhood-onset obesity (CO) compared to those with adult-onset obesity (AO). Weight loss can modify adipose tissue immune cell composition, but whether these changes differ by obesity onset remains unknown. Method ...

Article GUID: 40831565

Author(s): Carvajal Gonczi CM; Hajiaghayi M; Gholizadeh F; Xavier Soares MA; Touma F; Lopez Naranjo C; Rios AJ; Pozzebon C; Daigneault T; Burchell-Reyes K; Darlington PJ;

Background: T helper 17 (Th17) cells produce IL-17A cytokine and can exacerbate autoimmune diseases and asthma. The ß2 adrenergic receptor is a g protein-coupled receptor that induces cAMP second messenger pathways. We tested the hypothesis that terbutaline, a ß2-adrenergic receptor-specific agon ...

Article GUID: 37438188